pDC Activation by TLR7/8 Ligand CL097 Compared to TLR7 Ligand IMQ or TLR9 Ligand CpG.
Animals
Cell Differentiation
/ drug effects
Cytokines
/ immunology
Dendritic Cells
/ drug effects
Female
Imidazoles
/ pharmacology
Imiquimod
/ pharmacology
Interferon Inducers
/ pharmacology
Interferon Type I
/ immunology
Ligands
Membrane Glycoproteins
/ immunology
Mice
Mice, Inbred BALB C
Oligodeoxyribonucleotides
/ pharmacology
Quinolines
/ pharmacology
Thiazoles
/ pharmacology
Toll-Like Receptor 7
/ immunology
Toll-Like Receptor 8
/ immunology
Journal
Journal of immunology research
ISSN: 2314-7156
Titre abrégé: J Immunol Res
Pays: Egypt
ID NLM: 101627166
Informations de publication
Date de publication:
2019
2019
Historique:
received:
02
08
2018
revised:
19
01
2019
accepted:
24
02
2019
entrez:
17
5
2019
pubmed:
17
5
2019
medline:
8
8
2019
Statut:
epublish
Résumé
Plasmacytoid dendritic cells (pDCs) express high levels of the toll-like receptors (TLRs) TLR7 and TLR9. In response to TLR7 and TLR9 ligands, pDCs are primary producers of type I interferons. Our previous study demonstrated that pDCs activated by the TLR7 ligand imiquimod (IMQ) and the TLR9 ligand CpG A can kill breast cancer cells
Identifiants
pubmed: 31093508
doi: 10.1155/2019/1749803
pmc: PMC6481147
doi:
Substances chimiques
CL 075
0
CL097 compound
0
Cytokines
0
Imidazoles
0
Interferon Inducers
0
Interferon Type I
0
Ligands
0
Membrane Glycoproteins
0
Oligodeoxyribonucleotides
0
Quinolines
0
TLR8 protein, mouse
0
Thiazoles
0
Tlr7 protein, mouse
0
Toll-Like Receptor 7
0
Toll-Like Receptor 8
0
Imiquimod
P1QW714R7M
Types de publication
Journal Article
Langues
eng
Pagination
1749803Références
Gene Ther. 1999 Jul;6(7):1258-66
pubmed: 10455434
Eur J Immunol. 2004 Jan;34(1):251-62
pubmed: 14971051
Science. 2004 Mar 5;303(5663):1529-31
pubmed: 14976261
J Immunol. 2005 Feb 1;174(3):1259-68
pubmed: 15661881
Annu Rev Immunol. 2005;23:275-306
pubmed: 15771572
BMC Immunol. 2007 Oct 12;8:26
pubmed: 17935622
J Clin Invest. 2008 Mar;118(3):1165-75
pubmed: 18259609
J Immunol. 2008 Jun 1;180(11):7604-12
pubmed: 18490763
Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6442-7
pubmed: 20308556
Immunity. 2011 May 27;34(5):637-50
pubmed: 21616434
J Immunol. 2011 Dec 15;187(12):6346-56
pubmed: 22079988
J Immunol. 2012 Feb 15;188(4):1583-91
pubmed: 22231699
J Clin Invest. 2012 Feb;122(2):575-85
pubmed: 22251703
Cancer Res. 2012 Oct 15;72(20):5188-97
pubmed: 22836755
Oncoimmunology. 2013 Feb 1;2(2):e22983
pubmed: 23526329
Circ Res. 2014 May 9;114(10):1640-60
pubmed: 24812352
J Exp Med. 2014 Jun 2;211(6):1153-66
pubmed: 24842370
Lancet Oncol. 2014 Jun;15(7):e257-67
pubmed: 24872109
J Invest Dermatol. 2014 Jul;134(7):1797-1800
pubmed: 24924760
Tumour Biol. 2014 Oct;35(10):9661-6
pubmed: 24969556
Cancer Res. 2014 Nov 15;74(22):6430-40
pubmed: 25252912
Nat Rev Immunol. 2015 Aug;15(8):471-85
pubmed: 26160613
Oncotarget. 2017 Feb 14;8(7):11708-11718
pubmed: 28052019
Front Immunol. 2017 Oct 16;8:1268
pubmed: 29085361
Nat Immunol. 2018 Jan;19(1):63-75
pubmed: 29203862
Sci Transl Med. 2018 Jan 10;10(423):
pubmed: 29321259
Cancer Res. 2018 Jun 15;78(12):3280-3292
pubmed: 29588348
Immunol Cell Biol. 2018 Nov;96(10):1083-1094
pubmed: 29870118
Nature. 1998 Mar 19;392(6673):245-52
pubmed: 9521319